Literature DB >> 7690998

T lymphocytes ignore procainamide, but respond to its reactive metabolites in peritoneal cells: demonstration by the adoptive transfer popliteal lymph node assay.

M Kubicka-Muranyi1, R Goebels, C Goebel, J Uetrecht, E Gleichmann.   

Abstract

The drug procainamide (PA) is notorious for causing drug-induced systemic lupus erythematosus (SLE) in humans. Indirect evidence suggests that metabolism of PA to a reactive intermediate metabolite is involved in the pathogenesis of drug-induced SLE in that N-hydroxylation of the arylamine group of PA favors this condition, whereas N-acetylation prevents it. If this is correct, one would expect hydroxylamine-PA (HAPA) to be immunogenic, whereas N-acetyl-PA (N-ac-PA) should be nonimmunogenic. This hypothesis was confirmed by means of the popliteal lymph node assay (PLNA) in mice: injection of PA and N-ac-PA failed to induce a reaction in the direct PLNA, whereas HAPA induced a vigorous reaction. Using the adoptive transfer PLNA, splenic T cells of mice that had received three injections of HAPA were shown to be specifically sensitized to this metabolite, but not to PA or N-ac-PA. In this system, an anamnestic T cell response could also be elicited when homogenized peritoneal cells of mice that had been treated with PA for 4 months were used as the challenging antigen, indicating that the peritoneal cells of PA-treated animals contained or had been exposed to the reactive intermediate metabolite HAPA. Whereas in slow acetylator mice this 4-month PA treatment sufficed to generate HAPA in peritoneal cells, fast acetylators required additional stimulation of their oxidative metabolism in order to produce enough HAPA detectable by sensitized T cells. These findings clearly support the concept that reactive intermediate metabolites, such as HAPA, are generated by the oxidative metabolism of phagocytic cells and are immunogenic for T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690998     DOI: 10.1006/taap.1993.1175

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

1.  Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus.

Authors:  A Kretz-Rommel; S R Duncan; R L Rubin
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

2.  Orthopaedic implant related metal toxicity in terms of human lymphocyte reactivity to metal-protein complexes produced from cobalt-base and titanium-base implant alloy degradation.

Authors:  N J Hallab; K Mikecz; C Vermes; A Skipor; J J Jacobs
Journal:  Mol Cell Biochem       Date:  2001-06       Impact factor: 3.396

Review 3.  The toxic oil syndrome: an example of an exogenously induced autoimmune reaction. Toxic oil syndrome.

Authors:  S A Bell
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

4.  Phagocytes render chemicals immunogenic: oxidation of gold(I) to the T cell-sensitizing gold(III) metabolite generated by mononuclear phagocytes.

Authors:  C Goebel; M Kubicka-Muranyi; T Tonn; J Gonzalez; E Gleichmann
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

Review 5.  Screening tests for autoimmune-related immunotoxicity.

Authors:  R Pieters; R Albers
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

Review 6.  Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus.

Authors:  R L Rubin; A Kretz-Rommel
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

7.  Elevated levels of antibodies against xenobiotics in a subgroup of healthy subjects.

Authors:  Aristo Vojdani; Datis Kharrazian; Partha Sarathi Mukherjee
Journal:  J Appl Toxicol       Date:  2014-07-18       Impact factor: 3.446

8.  Cross-Reactivity between Chemical Antibodies Formed to Serum Proteins and Thyroid Axis Target Sites.

Authors:  Datis Kharrazian; Martha Herbert; Aristo Vojdani
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.